JPWO2020092533A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020092533A5 JPWO2020092533A5 JP2021548551A JP2021548551A JPWO2020092533A5 JP WO2020092533 A5 JPWO2020092533 A5 JP WO2020092533A5 JP 2021548551 A JP2021548551 A JP 2021548551A JP 2021548551 A JP2021548551 A JP 2021548551A JP WO2020092533 A5 JPWO2020092533 A5 JP WO2020092533A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- immunoconjugate
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015899A JP2025072466A (ja) | 2018-10-30 | 2025-02-03 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752832P | 2018-10-30 | 2018-10-30 | |
| US62/752,832 | 2018-10-30 | ||
| US201962860565P | 2019-06-12 | 2019-06-12 | |
| US62/860,565 | 2019-06-12 | ||
| US201962881137P | 2019-07-31 | 2019-07-31 | |
| US62/881,137 | 2019-07-31 | ||
| PCT/US2019/058824 WO2020092533A2 (en) | 2018-10-30 | 2019-10-30 | Methods of treatment using anti-cd123 immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015899A Division JP2025072466A (ja) | 2018-10-30 | 2025-02-03 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513405A JP2022513405A (ja) | 2022-02-07 |
| JPWO2020092533A5 true JPWO2020092533A5 (https=) | 2022-11-08 |
| JP2022513405A5 JP2022513405A5 (https=) | 2022-11-08 |
| JP7630435B2 JP7630435B2 (ja) | 2025-02-17 |
Family
ID=70464182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548551A Active JP7630435B2 (ja) | 2018-10-30 | 2019-10-30 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
| JP2025015899A Pending JP2025072466A (ja) | 2018-10-30 | 2025-02-03 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015899A Pending JP2025072466A (ja) | 2018-10-30 | 2025-02-03 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200157228A1 (https=) |
| EP (1) | EP3873524B8 (https=) |
| JP (2) | JP7630435B2 (https=) |
| KR (1) | KR20210087951A (https=) |
| CN (2) | CN118557748A (https=) |
| AU (1) | AU2019370291B2 (https=) |
| CA (1) | CA3117493A1 (https=) |
| IL (1) | IL282685A (https=) |
| MA (1) | MA54088A (https=) |
| SG (1) | SG11202103999VA (https=) |
| TW (1) | TWI870363B (https=) |
| WO (1) | WO2020092533A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3137454A1 (en) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Therapeutic combinations comprising anti-cd123 immunoconjugates |
| US20250345449A1 (en) * | 2024-05-10 | 2025-11-13 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| WO2008127735A1 (en) * | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| JP2011509675A (ja) | 2008-01-18 | 2011-03-31 | メディミューン，エルエルシー | 部位特異的コンジュゲーションのためのシステイン操作抗体 |
| AU2010270979B2 (en) | 2009-06-22 | 2015-04-23 | Medimmune, Llc | Engineered Fc regions for site-specific conjugation |
| SI2900277T1 (sl) * | 2012-12-13 | 2022-05-31 | Immunomedics, Inc. | Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost |
| CA2911499A1 (en) * | 2013-05-14 | 2014-11-20 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| CN115124573A (zh) * | 2013-09-02 | 2022-09-30 | 杭州多禧生物科技有限公司 | 应用于细胞结合分子-药物共轭体的新型细胞毒性分子 |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| ES2887273T3 (es) | 2015-06-29 | 2021-12-22 | Immunogen Inc | Anticuerpos anti-CD123 y conjugados y derivados de los mismos |
| EP3769787A1 (en) | 2015-06-29 | 2021-01-27 | ImmunoGen, Inc. | Conjugates of cysteine engineered antibodies |
| TWI845890B (zh) * | 2016-11-23 | 2024-06-21 | 美商伊繆諾金公司 | 苯二氮平衍生物之選擇性磺化 |
| TW202021618A (zh) * | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
-
2019
- 2019-10-30 US US16/668,257 patent/US20200157228A1/en not_active Abandoned
- 2019-10-30 CN CN202410406681.5A patent/CN118557748A/zh active Pending
- 2019-10-30 JP JP2021548551A patent/JP7630435B2/ja active Active
- 2019-10-30 CN CN201980073676.4A patent/CN113329768A/zh active Pending
- 2019-10-30 CA CA3117493A patent/CA3117493A1/en active Pending
- 2019-10-30 WO PCT/US2019/058824 patent/WO2020092533A2/en not_active Ceased
- 2019-10-30 AU AU2019370291A patent/AU2019370291B2/en active Active
- 2019-10-30 EP EP19878291.4A patent/EP3873524B8/en active Active
- 2019-10-30 MA MA054088A patent/MA54088A/fr unknown
- 2019-10-30 KR KR1020217014003A patent/KR20210087951A/ko active Pending
- 2019-10-30 TW TW108139297A patent/TWI870363B/zh active
- 2019-10-30 SG SG11202103999VA patent/SG11202103999VA/en unknown
-
2021
- 2021-04-27 IL IL282685A patent/IL282685A/en unknown
-
2022
- 2022-11-09 US US18/054,076 patent/US20230312735A1/en active Pending
-
2025
- 2025-02-03 JP JP2025015899A patent/JP2025072466A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021508469A5 (https=) | ||
| JPWO2019129221A5 (https=) | ||
| CA2932567A1 (en) | Caninized murine antibodies to human pd-1 | |
| EP4139347A1 (en) | Anti-cd3 antibodies and uses thereof | |
| JP2023089245A5 (https=) | ||
| JP2021525805A (ja) | イメージングのための組成物および方法 | |
| EP4532547A1 (en) | Antibodies that bind to human ccr8 | |
| CN112533952A (zh) | 治疗疾病或病况的组合物及其用途 | |
| JP2020528936A5 (https=) | ||
| CN101796073B (zh) | 针对cxcr3的人源化抗体 | |
| CN106794231A (zh) | 用于慢性淋巴细胞性白血病（cll）的治疗 | |
| JP2025156341A (ja) | ＰＤ－１アンタゴニスト、ＨＩＦ－２α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| JPWO2020011973A5 (https=) | ||
| JPWO2019141732A5 (https=) | ||
| WO2022108976A2 (en) | Anti-gpa33 multi-specific antibodies and uses thereof | |
| CN116710132A (zh) | 抗ilt4抗体或其与抗pd-1抗体的组合用于治疗癌症的给药方案 | |
| JPWO2020092533A5 (https=) | ||
| CN114829405A (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| KR20220123017A (ko) | Pd-1 길항제, ilt4 길항제 및 화학요법제의 조합물을 사용하여 암을 치료하는 방법 | |
| RU2021111258A (ru) | Способы лечения с использованием анти-cd123 иммуноконъюгатов | |
| JPWO2020123664A5 (https=) | ||
| JP2025541340A (ja) | Ｃｕｂ ｄｏｍａｉｎ－ｃｏｎｔａｉｎｉｎｇ ｐｒｏｔｅｉｎ １（ｃｄｃｐ１）に対する抗体およびその使用 | |
| JPWO2023028653A5 (https=) | ||
| JPWO2019228514A5 (https=) | ||
| JP2024531220A (ja) | Ｔｉｇｉｔアンタゴニスト、ｐｄ－１アンタゴニスト、及びレンバチニブを含む治療薬の組み合わせ |